BACKGROUND: Negative clinical trials foster therapeutic nihilism and public skepticism, especially if they follow optimistic preclinical results. One way to increase the likelihood
Abstract Background With obesity as a risk factor for atherosclerotic disease, recent research suggests that adipose tissue in obese animal models and humans can generate endocrine
Sound mechanistic and preclinical work demonstrating a novel ERRα activator protects against anthracycline cardiotoxicity in animal models with direct target engagement, but lacks clinical trial data in human patients.